Recent advances in the bench-to-bedside translation of cancer nanomedicines

被引：1
作者：
Liu, Yang [1 ,2 ]
Zhang, Yinchao [1 ]
Li, Huikai [1 ,2 ]
Hu, Tony Y. [3 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Tianjins Clin Res Ctr Canc, Liver Canc Ctr, Natl Clin Res Ctr Canc,Dept Hepatobiliary Canc,Key, Tianjin 300060, Peoples R China
[2] Tianjin Canc Hosp Airport Hosp, Natl Clin Res Ctr Canc, Dept Hepatobiliary & Pancreat Oncol, Tianjin 300308, Peoples R China
[3] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA
来源：
ACTA PHARMACEUTICA SINICA B | 2025年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Cancer nanomedicines; Clinical translation; Clinical trial landscape; Anticancer; Tumor microenvironment; Combination therapies; Clinical nanotechnology; Drug delivery systems; TARGETED DRUG-DELIVERY; TUMOR MICROENVIRONMENT; PHOTOTHERMAL THERAPY; BREAST-CANCER; IN-VIVO; EXTRACELLULAR VESICLES; NANOPARTICLES; CHALLENGES; NANOMATERIALS; VACCINES;
D O I：
10.1016/j.apsb.2024.12.007
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cancer remains a complex and challenging medical problem, driving extensive research efforts. Despite significant progress in understanding its genetic and molecular aspects, the quest for effective treatments continues. Nanomedicines have shown great potential for revolutionizing cancer treatment by offering targeted and controlled drug delivery, reducing side effects, and improving patient outcomes. Accordingly, nanomedicines have been the focus of extensive research and development for clinical translation. As of September 2024, a search on the ClinicalTrials.gov website using the term "nanoparticles" revealed numerous ongoing and planned clinical trials. Motivated by recent advances in the field, this review explores the current frontier of cancer nanomedicine. Nanomedicines have supported chemotherapy, phototherapy and sonodynamic therapy, nucleic acid therapy, and immunotherapy. However, translating nanomedicines into practice has been challenged by complex interactions between nanoparticles and biological systems, variable permeability and retention of nanoparticles in tumors, safety concerns, difficulty achieving targeted delivery, and issues with scaling up manufacturing. Perspectives on addressing these challenges are offered. Future opportunities for cancer nanomedicines, including modifying the tumor microenvironment, integrating artificial intelligence and big data, and targeting new medical areas, are also discussed. This review underscores the potential of cancer nanomedicines to revolutionize treatment from a clinical standpoint.
引用
收藏
页码：97 / 122
页数：26
相关论文
共 169 条
  • [1] Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 74, pp. 229-263, (2024)
  • [2] Han B., Zheng R., Zeng H., Wang S., Sun K., Chen R., Et al., Cancer incidence and mortality in China, 2022, J Natl Cancer Cent, 4, pp. 47-53, (2024)
  • [3] Soerjomataram I., Bray F., Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070, Nat Rev Clin Oncol, 18, pp. 663-672, (2021)
  • [4] Sharma P., Allison J.P., The future of immune checkpoint therapy, Science, 348, pp. 56-61, (2015)
  • [5] Li Q., Shi Z., Zhang F., Zeng W., Zhu D., Mei L., Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle, Acta Pharm Sin B, 12, pp. 107-134, (2022)
  • [6] Kang W., Liu Y., Wang W., Light-responsive nanomedicine for cancer immunotherapy, Acta Pharm Sin B, 13, pp. 2346-2368, (2023)
  • [7] Dang Y., Guan J., Nanoparticle-based drug delivery systems for cancer therapy, Smart Mater Med, 1, pp. 10-19, (2020)
  • [8] Peng X., Fang J., Lou C., Yang L., Shan S., Wang Z., Et al., Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy, Acta Pharm Sin B, 14, pp. 3432-3456, (2024)
  • [9] Wolfram J., Zhu M., Yang Y., Shen J., Gentile E., Paolino D., Et al., Safety of nanoparticles in medicine, Curr Drug Targets, 16, pp. 1671-1681, (2015)
  • [10] Mosleh-Shirazi S., Abbasi M., reza Moaddeli M., Vaez A., Shafiee M., Kasaee S.R., Et al., Nanotechnology advances in the detection and treatment of cancer: an overview, Nanotheranostics, 6, (2022)
12345678910